Haiyi Guo
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Association of the aggregate index of systemic inflammation in cancer survivors with all-cause, cardiovascular, and cancer-related mortality.
Journal: Translational cancer research
Published: September 15, 2025
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
Journal: Leukemia & lymphoma
Published: February 17, 2023
A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma.
Journal: Leukemia & lymphoma
Published: July 20, 2022
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.
Journal: British journal of haematology
Published: December 16, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
Journal: Blood advances
Published: July 01, 2021
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 10, 2021
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 03, 2021
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Journal: Journal of hematology & oncology
Published: March 05, 2020
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 11, 2019
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
Journal: Leukemia
Published: February 27, 2019
Last Updated: 09/26/2026